Log on / register
Feedback | Support | My details
A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E, 301 Study Group
BMC Infect Dis 2005, 5:88
[Full text] [PubMed] [Related articles]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG
Antimicrob Agents Chemother 2007 Jun, 51:1939-45
 [PubMed Central] [PubMed] [Related articles]
2.
Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.
Townsend ML, Pound MW, Drew RH
Ther Clin Risk Manag 2007 Dec, 3:1059-70
 [PubMed Central] [PubMed] [Related articles]
3.
Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.
Boada JN, Boada C, García-Sáiz M, García M, Fernández E, Gómez E
PLoS ONE 2008, 3:e3580
 [PubMed Central] [PubMed] [Related articles]

You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.